• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
COVID-19 Testing

Efficacy of the Novavax SARS-CoV-2 Vaccine Against UK and South African Variants

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Novavax’s SARS-CoV-2 vaccine is 95.6% effective against the original SARS-CoV-2 variant, requires 2 doses 3 weeks apart, and can be stored at 2 to 8 degrees Celsius
  • The BMJ (Feb 2021) summarizes interim results on the vaccine’s effectiveness against the UK and South African variants of SARS-CoV-2

METHODS:

  • Interim results from a phase III trial in the UK and a phase II trial in South Africa
  • Participants
    • Individuals aged 18 to 84
  • Interventions
    • Two doses of the Novavax vaccine administered 3 weeks apart
    • Placebo

RESULTS:

  • Participants
    • UK: 5,000
    • South Africa: 4400

UK phase III trial

  • SARS-CoV-2 infections identified
    • Placebo group: 56 cases
    • Vaccine group: 6 cases
  • Only one severe COVID-19 case was identified, and this was in the placebo group
  • Of all cases identified, 32 were of the UK variant

South African phase II trial

  • SARS-CoV-2 infections identified
    • Placebo group: 29 cases
    • Vaccine group: 15 cases
  • Only one severe COVID-19 case was identified, and this was in the placebo group
  • In preliminary sequencing data of 27 cases, 93% involved the South African variant

CONCLUSION:

  • Preliminary interim data indicates that the Novavax SARS-CoV2 vaccine is 85.6% effective against the UK variant (B.1.1.7) and 60% effective against the South African variant (B.1.351)
  • Clinical Trials are ongoing, including in the US and Mexico

Learn More – Primary Sources:

Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant

How the Novavax Covid-19 Vaccine Works – The New York Times

Get COVID-19 Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All COVID-19 Testing Posts
Next >

Related ObG Topics:

Safety and Efficacy Data of BNT162b2 COVID-19 Vaccine
Safety and Efficacy of AstraZeneca Oxford’s COVID-19 Vaccine
The Moderna Vaccine: Study Results Presented to ACIP CDC Committee

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site